# David M. O’Malley

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-m-o-malley/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,367 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 89 |
| i10-index | 312 |
| Last Known Institution | The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute |
| OpenAlex ID | https://openalex.org/A5021359849 |
| ORCID iD | 0000-0002-2828-0177 |
| Works | 885 |

## Researcher papers

Showing 12 of 24.

- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/rucaparib-in-relapsed-platinum-sensitive-high-grade-ovarian-carcinoma-ariel2/)
- [Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/ovarian-cancer-version-2-2020-nccn-clinical-practice-guidelines-in-oncology/)
- [Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial](https://scholariq.org/papers/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction/)
- [Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer](https://scholariq.org/papers/identification-of-12-new-susceptibility-loci-for-different-histotypes-of/)
- [Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu](https://scholariq.org/papers/randomized-phase-ii-trial-of-carboplatin-paclitaxel-versus-carboplatin/)
- [Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study](https://scholariq.org/papers/pembrolizumab-in-patients-with-microsatellite-instability-high-advanced/)
- [Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer](https://scholariq.org/papers/adjuvant-chemotherapy-plus-radiation-for-locally-advanced-endometrial-cancer/)
- [<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma](https://scholariq.org/papers/i-brca-i-reversion-mutations-in-circulating-tumor-dna-predict-primary-and/)
- [Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/efficacy-and-safety-of-tisotumab-vedotin-in-previously-treated-recurrent-or/)
- [A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)](https://scholariq.org/papers/a-randomized-phase-iii-trial-to-evaluate-rucaparib-monotherapy-as-maintenance/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute](https://scholariq.org/institutions/the-ohio-state-university-comprehensive-cancer-center-arthur-g-james-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.